FOF/VC  DSM Venturing

http://www.dsm.com/corporate/about/business-e ntities/dsm-venturing.html





     Office Locations:

1 Broadway, 14th Floor
Cambridge, MA 02142
Phone: 617-531-2129

Get all office locations for this firm with a National Database subscription or Silicon Valley Database subscription.
 

Stages:

  • Early
  • Expansion


 

Industries:

  • Information Technology
  • Life Sciences & Healthcare
  • Manufacturing & Industrial

  •  

    Description:

    Headquartered in the Netherlands, DSM Venturing is an active investor in start-up companies. The firm looks for innovative products and services in Life Sciences and Materials Sciences in the fields Climate & Energy, Functionality & Performance, Health & Wellness, and Emerging Economies. DSM Venturing's mission is to explore emerging markets and technologies in order to support DSM's innovation and growth strategy. DSM Venturing participates in early and expansion stage companies or venture capital funds as a value adding partner. The firm's investments typically range between EURO 0.5 and EURO 5 million (no fixed upper limit). DSM's share target range in companies is 10% to 25% share. The firm currently has about EURO 60 million invested in promising companies and leading venture capital funds. DSM goes where the growth is, focusing on regions that generate the most opportunities, including China, India, Russia, and Brazil.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    Casper Bruens Senior investment Manager
    Erik Rutten Senior Investment Manager
    Greg McParland Investment Manager
    Ian Freelance Senior investment Manager
    Pieter Wolters Managing Director

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      04/25/2018


      Chromatic 3D Materials


      MN


      undisclosed


      Series A


     

    Portfolio companies include:


      Agennix
        web link


      Bioprocess Control
        web link


      Cambrios
        web link


      Cellmade
        web link


      Chromatic 3D Materials
        web link


      Ganeden Biotech
        web link


      Harland Medical Systems
        web link


      InMat
        web link


      IntegraGen SA
        web link


      IQ Therapeutics
        web link


      NanoHoldings
        web link


      Novomer
        web link


      Provexis
        web link


      Qolpac
        web link


      Regentis Biomaterials
        web link


      Segetis
        web link


      SkySails GmbH & Co
        web link


      Sol-Gel Technologies
        web link


      Suprabolix
        web link


      SupraPolix
        web link


      Tianjin Green Bio-Science
        web link


      Upfront Chromatography
        web link


      Van Technologies
        web link


      Verdezyne
        web link


      Viocare
        web link


      Xolve
        web link


      Xylos
        web link


      ZeaVision Holdings
        web link


     

    Recent News: